Fundraising FoxNerio Therapeutics
acquired by Boehringer IngelheimLa Jolla, US · Founded 2019 · Delaware corporation · 1 known investors
Find your way into Nerio Therapeutics
Sign up to see every warm intro you have to Nerio Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nerio Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Phosphatase-focused immunotherapy drug discovery company; acquired by Boehringer-Ingelheim for up to $1.3B in 2024.
Founders & leadership
SH
Stefan HellerNamed on SEC filing
SJ
Sanford J. Madigan, Ph.D.Named on SEC filing
Board
TR
Tighe ReardonBoard directorInvestor at Avalon Ventures Management, Llc
JL
Jay Lichter, Ph.D.Board director
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.5M disclosed across 2 rounds · 2020–2021
▶$3.5MraisedOct 2021 · 5 investors · BiotechnologyRule 506(b)
▶$3.5MraisedOct 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sanford J. Madigan, Ph.D.Executive Officer, Director
- Jay Lichter, Ph.D.Director
- Tighe ReardonExecutive Officer, Director
- Stefan HellerDirector
- Offering amount
- $10M
- Amount sold
- $3.5M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3MraisedJul 2020 · 5 investors · BiotechnologyRule 506(b)
▶$3MraisedJul 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tighe ReardonExecutive Officer, Director
- Stefan HellerDirector
- Sanford J. Madigan, Ph.D.Executive Officer, Director
- Jay Lichter, Ph.D.Director
- Offering amount
- $5.8M
- Amount sold
- $3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nerio Therapeutics do?
- Phosphatase-focused immunotherapy drug discovery company; acquired by Boehringer-Ingelheim for up to $1.3B in 2024.
- Who are Nerio Therapeutics's investors?
- Nerio Therapeutics's investors include Avalon BioVentures.
- How much funding has Nerio Therapeutics raised?
- Nerio Therapeutics has disclosed $6.5M raised across 2 rounds.
- Who acquired Nerio Therapeutics?
- Nerio Therapeutics was acquired by Boehringer Ingelheim.
- Where is Nerio Therapeutics headquartered?
- Nerio Therapeutics is headquartered in La Jolla, US.